Study of IBR733 Cell Injection in Acute Myeloid Leukemia - Trial NCT06234904
Access comprehensive clinical trial information for NCT06234904 through Pure Global AI's free database. This Phase 1 trial is sponsored by Imbioray (Hangzhou) Biomedicine Co., Ltd. and is currently Not yet recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 18 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Timeline & Enrollment
Phase 1
Feb 01, 2024
Aug 01, 2025
Primary Outcome
Incidence of dose limiting toxicity (DLT),The incidence and severity of adverse events (AEs)
Summary
This is an open-label clinical study: phase Ia is the dose-escalation part, and phase Ib is
 the dose-expansion part. The phase Ia study is to evaluate the safety, tolerability,
 recommended phase II dose, pharmacokinetics, immunogenicity and preliminary efficacy of
 IBR733 cell injection in relapsed/refractory acute myeloid leukemia (AML).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06234904
Non-Device Trial